Eduardo Albornoz Balmaceda

Dr Albornoz’s research investigates how environmental, infectious, and disease-related factors trigger harmful inflammatory responses in the brain that contribute to neurodegenerative disease progression.

His work helped validate the NLRP3 inflammasome as a therapeutic target in Parkinson’s disease and contributed to the development of next-generation inflammasome inhibitors through collaboration with Inflazome, later acquired by Roche. His research has also contributed to understanding how complement and inflammasome pathways interact to amplify chronic neuroinflammation and neuronal injury in neurodegenerative disease. Together, this work formed part of translational drug development programs progressing towards clinical testing and contributed to one of UQ’s most successful biomedical commercialisation outcomes.

His studies on SARS-CoV-2, neuroinflammation, and cellular senescence provided some of the first mechanistic evidence linking viral infection to activation of inflammatory pathways associated with neurodegeneration. This work received international attention through extensive media coverage, strong citation impact, and recognition as a highly cited and “hot” publication.

A major focus of Dr Albornoz’s research is understanding how multiple environmental, infectious, and disease-related “hits” interact to amplify chronic inflammation, neuronal injury, cellular dysfunction, and self-sustaining cycles of immune activation in the brain. This work aims to improve understanding of modifiable disease risk factors and identify opportunities for earlier therapeutic intervention, disease prevention, and development of new immunomodulatory therapies.

His research also contributes to development of advanced human-relevant experimental models, including patient-derived microglia and human brain organoids, supporting more predictive preclinical testing and translational neuroscience research.

Through collaborations with academic, biotechnology, and clinical research partners, his work supports the translation of neuroimmunology discoveries into therapeutic development and improved understanding of neurodegenerative disease mechanisms.